Articles tagged with Monoclonal Antibodies
Researchers developed a viral panel that enables simultaneous testing for SARS-CoV-2 and common respiratory viruses, providing insight into coinfections and viral spread. The tool helps predict and mitigate future outbreaks by tracking novel viral variants and their patterns of spread.
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
A new protocol combining patient monitoring and monoclonal antibody therapy reduced hospitalizations by half and deaths to zero for eligible patients. The study, conducted at Keck Medicine of USC, shows improved outcomes among liver and kidney transplant recipients with COVID-19.
Scientists have discovered antibodies that block the SARS-CoV-2 virus from entering cells in preclinical models. The discovery paves the way for clinical trials of monoclonal antibody treatments to prevent severe COVID-19 infection, and could provide immediate protection against the virus.
A global collaboration has identified three groups of antibodies resistant to mutations in the SARS-CoV-2 Spike protein, which could target vulnerable sites on the protein. The study provides a framework for selecting durable antibody cocktails for COVID-19 treatment and will guide the development of more effective antibody therapies.
A Vanderbilt University Medical Center technology has led to the discovery of an 'ultra-potent' monoclonal antibody that neutralizes SARS-CoV-2 and its variants. The antibody's unique characteristics make it a valuable addition to therapeutic candidates.
Researchers compared COVID-19 treatment outcomes among high-risk Native American patients who received versus did not receive monoclonal antibodies. The study found significant disparities in treatment response and mortality rates among this population.
Researchers developed a liquid-injecting self-orienting millimeter-scale applicator (L-SOMA) that administers typically injected liquid medications orally. In large animal preclinical models, the technology delivered four commonly injected medications with comparable results to injections.
A Mayo Clinic study found that a combination of casirivimab and imdevimab reduced hospitalization rates among high-risk patients with mild to moderate COVID-19 by 60%–70%. The treatment allowed these patients to recover safely at home.
A team of MIT engineers has developed a drug delivery capsule that can inject large quantities of monoclonal antibodies and other proteins into the stomach lining after being swallowed. The capsule overcomes a major challenge in delivering these drugs orally, which are usually administered via injections.
Researchers at UNC Chapel Hill engineered ultra-potent antibodies that effectively trapped and blocked over 99.9% of human sperm during animal testing. The promising results suggest an alternative non-hormonal option to prevent pregnancy may be available.
Researchers at WashU Medicine have identified an antibody that is highly protective at low doses against a wide range of viral variants. The antibody targets a part of the virus' spike protein that differs little across variants, making it unlikely to lose potency as the virus mutates.
A new monoclonal antibody called CIS43LS safely prevented malaria for up to nine months in a small clinical trial. The study builds on encouraging early results and will inform additional research to confirm and extend the finding.
Immunocompromised individuals are at risk for prolonged viral shedding and the emergence of novel variants of concern. Healthcare providers must develop precise guidelines for monitoring and treating these patients.
A large observational study found that two monoclonal antibodies reduced hospitalizations among high-risk patients with COVID-19, regardless of comorbidities. The study showed a low rate of hospitalizations when patients received the treatment early on.
A recent study has identified a panel of human monoclonal antibodies that can neutralize a broad range of norovirus variants. The researchers discovered a conserved antigenic site on the virus that could be used to reformulate vaccine candidates for broad effectiveness.
A study by USF Health and Tampa General Hospital found that early administration of monoclonal antibodies to high-risk patients can significantly reduce COVID-19-related emergency department visits and hospitalizations. The treatment reduced hospitalization rates by 40.5% compared to controls, with no deaths reported in the treated group.
A recent study published in Open Forum Infectious Diseases found that monoclonal antibody therapy is safe and effective in treating mild to moderate cases of COVID-19 in transplant patients. The study showed that these patients had a lower risk of severe illness and death compared to those who did not receive the treatment.
A new study found that an inhalable nanobody-based treatment can effectively prevent and treat SARS-CoV-2 infections in Syrian hamsters. The treatment, PiN-21, prevents significant weight loss and eliminates the virus after 10 days, regardless of the original route of viral entry.
Monoclonal antibodies cut COVID-19 risk of hospitalization and death by 60% in those most likely to suffer complications. The strongest effect was seen in older patients, who were nearly three times less likely to be hospitalized or die.
Researchers rationally designed a new monoclonal antibody HA98 with improved affinity for CD146, a key adhesion molecule in angiogenesis and cancer metastasis. The study revealed superior inhibitory effects on tumor growth compared to the original AA98 antibody.
The UPMC/Pitt team established a largest and most equitable distribution network for COVID-19 monoclonal antibody infusions across Pennsylvania. The treatment reduced likelihood of hospitalization and death in UPMC patients who received it, especially when administered soon after infection.
A new study published in Nature Communications shows that combining monoclonal antibodies and remdesivir is effective in treating advanced Marburg virus disease. The combination therapy demonstrated an 80% protection rate against the lethal virus, offering promise for treatment of advanced infections.
The ACTIV-3 clinical trial has closed enrollment in two sub-studies, one examining the monoclonal antibody therapy VIR-7831 and another evaluating the combination therapy BRII-196 and BRII-198. The trials were halted due to futility, with no safety concerns reported.
A monoclonal antibody 'cocktail' developed at Vanderbilt University Medical Center effectively neutralizes all known COVID-19 variants. The treatment, comprising two antibodies isolated from previously infected individuals, targets sites on the spike protein other than the highly mutable E484K residue.
Scientists at The Wistar Institute, INOVIO, AstraZeneca, and Indiana University are developing synthetic DNA-encoded monoclonal antibodies (DMAbs) to combat COVID-19. These novel therapeutics instruct the body to produce highly specific antibodies against pathogens, offering advantages in scale-up and delivery.
Researchers identified nanobodies that bind tightly to the SARS-CoV-2 spike protein, providing a unique prophylactic and therapeutic strategy. These therapeutics have the potential to be produced in bulk from microbes and delivered via aerosol, offering an affordable alternative to monoclonal antibodies.
Researchers at the University of Pittsburgh School of Medicine developed a fast method to identify effective human monoclonal antibodies against SARS-CoV-2. The team successfully isolated Ab1, a potent antibody that neutralizes COVID-19 by binding to the virus's receptor binding domain.
A Phase II clinical trial found that LY-CoV555, a monoclonal antibody, lowered viral load and reduced hospitalization rates in outpatients with mild to moderate COVID-19. The treatment was effective across all demographic groups, including high-risk patients.
Scientists at University of Bath and UCB biopharma company produce miniaturized antibodies up to five times smaller than regular ones. These tiny antibodies may bind to sites on pathogens that larger antibodies can't, offering a potential new class of treatments.
Researchers at MassBiologics discovered a cross-reactive human monoclonal antibody to SARS-CoV-2 spike proteins, blocking ACE2 receptor binding and potentially preventing or limiting COVID-19 disease. The antibodies, in the sIgA isotype, exhibited higher binding affinity and neutralization activity than usual circulating IgG antibodies.
The COVID-19 Prevention Network is launching two Phase 3 trials to evaluate the effectiveness of LY-CoV555 and REGN-COV-2 monoclonal antibodies in preventing SARS-CoV-2 infection among high-risk groups. These trials aim to explore the potential of mAbs as a rapid solution to prevent COVID-19 acquisition.
A Phase 2 clinical trial is testing the safety and efficacy of synthetic monoclonal antibodies to treat COVID-19. The study aims to reduce the duration of symptoms and increase the proportion of participants with undetectable virus in nasopharyngeal swabs.
Human monoclonal antibodies isolated from infected children neutralize enterovirus D68 and protect against infection and paralytic disease. The antibodies, which recognize diverse antigenic variants, show high potency and effectiveness in animal models.
Researchers uncovered novel mechanisms of protective antibodies against Marburg virus infection through a study of monoclonal antibodies from a survivor. The findings suggest that these antibodies recruit immune cells to kill infected cells and strengthen the protective effect by rearranging the viral glycoprotein. This research provid...
Researchers have visualized a broadly neutralizing human monoclonal antibody, RVC20, which blocks the entry of the rabies virus into cells. The findings highlight new perspectives for prevention and treatment of the deadly disease.
A Phase 1 clinical trial tests the safety and effectiveness of mAb CIS43LS in preventing malaria infection. Volunteers will receive a single dose of the antibody and then be exposed to malaria-carrying mosquitoes to assess protection.
BIOCAD announces plans to introduce netakimab and progolimab, two original monoclonal antibody-based drugs, to the European market. The company has already received permission to conduct clinical trials in Europe for these innovative treatments.
A potent monoclonal antibody has been developed to impede henipavirus fusion with cell membranes, blocking viral genome injection. The antibody recognizes a specific area of the viral membrane machinery, preventing membrane fusion and keeping viral material out of host cells.
Research presented at the IASLC 2019 World Conference on Lung Cancer found that combining nivolumab with ipilimumab showed improved efficacy in patients with advanced non-small cell lung cancer (NSCLC), particularly those with high TMB or higher tumor PD-L1 expression. The safety profile of this combination therapy was also consistent ...
Researchers identify antigens targeted by the antibody response of children with Kawasaki Disease, strongly suggesting a new human virus is etiologically related. The study found that monoclonal antibodies from these patients recognized peptides from a hepacivirus non-structural protein.
Researchers have developed a synthetic DNA-encoded monoclonal antibody that rapidly protects mice and non-human primates from Zika infection. The DMAb-ZK190 platform has shown promise in controlling infection and reducing viral loads, providing a potential alternative to existing prevention methods.
An investigational monoclonal antibody, mAb114, has been found to be safe and well-tolerated in an early-stage clinical trial involving adults. The treatment, which targets the Ebola virus's surface protein, demonstrated promising results, with all participants experiencing mild side effects.
A study using murine models found that a neutralizing monoclonal antibody, ZIKV-195, protects mice from Zika virus infection. The antibody targets and cross-links envelope proteins critical for viral membrane fusion.
Researchers at Vanderbilt University Medical Center have isolated a human monoclonal antibody that can neutralize the West Nile virus, potentially preventing viral encephalitis in the US. The study found that a single dose of this antibody completely protected mice from an otherwise lethal West Nile infection.
Scientists at The Wistar Institute have successfully engineered novel DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus, which offered complete and long-term protection against lethal virus challenges. The study provides a simple, rapid, and reproducible approach for immunization and evaluation of antibody efficacy.
Researchers describe a DNA immunization platform that stimulates innate and adaptive immunity to produce high levels of antigen-specific antibody responses. The approach activates multiple pathways of innate immunity, leading to the development of high-affinity antibodies in mouse, rabbit, and human models.
Researchers at The Wistar Institute developed synthetic DNA-encoded monoclonal antibodies targeting CTLA-4, achieving antitumor activity comparable to traditional monoclonals. The approach stimulates robust CD8+ T-cell infiltration and tumor clearance in mouse models.
Researchers at IBBR have engineered three mouse cell lines to produce nonproprietary versions of the NISTmAb, a well-characterized monoclonal antibody used in biopharmaceutical development. The new cell lines will provide a standardized model for monoclonal antibody biomanufacturing and enable innovation in mAb therapeutics.
Researchers developed a monoclonal antibody targeting BamA in Gram-negative bacteria, inhibiting its function and compromising outer membrane integrity. The treatment shows promise for developing therapeutics against these bacteria.
Researchers from NIAID highlight the potential of monoclonal antibodies in treating and preventing emerging infectious diseases. These therapies have shown promise in clinical trials, such as the Ebola outbreak, and may offer a more targeted approach to infection prevention and treatment.
A new enzyme-linked immunosorbent assay (ELISA) for bioanalysis of bevacizumab has been developed with a high sensitivity and selectivity. The assay limits detection to 1.01 ng/mL and offers an effective working dynamic range of 3.07-100 ng/mL.
Scientists develop an antibody-based Zika virus therapeutic that protects monkeys from infection and neutralizes the virus. The treatment has been shown to be effective in preventing Zika virus replication in rhesus macaques.
A collaborative study has found that a combination of three monoclonal antibodies prevents Zika virus infection in primates. The treatment completely blocked the virus from taking hold in the animals, indicating a promising intervention to protect uninfected pregnant women and their fetuses.
Scientists have identified two natural human antibodies that can neutralize all five known ebolaviruses, offering a breakthrough in the fight against these deadly viruses. The antibodies work by interfering with the virus's ability to infect cells, preventing it from multiplying and causing disease.
A new study confirms denosumab's short-term and long-term safety in treating postmenopausal osteoporosis. Women on long-term treatment experienced no increase in adverse effects compared to those on placebo or shorter treatment durations.
A successful antibody treatment protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected. Monoclonal antibodies show promise in providing protection during advanced stages of disease with highly dangerous viruses.
Scientists have successfully treated guinea pigs and rhesus monkeys with a monoclonal antibody to cure Marburg and Ravn viruses. The treatment, MR191-N, provided up to 100% protection when administered within 5 days of infection, offering new hope for preventing and treating filovirus outbreaks.
A new study found denosumab safe for treating postmenopausal osteoporosis over an extended period. The monoclonal antibody showed no increased risk of adverse events after 6 years of treatment, confirming its excellent safety and tolerability profile.
A new study published in the American Journal of Respiratory and Critical Care Medicine found that preterm babies who received palivizumab had significantly lower incidence of physician-diagnosed wheeze by age six, compared to those who did not receive the drug. The researchers suggest that atopic asthma in children up to age six is pr...